(Translated by https://www.hiragana.jp/)
Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer

Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer

Am J Clin Oncol. 2008 Dec;31(6):585-8. doi: 10.1097/COC.0b013e318174dbd2.

Abstract

Objectives: The present study was conducted to investigate the sensitivity, specificity, predictive values and accuracy of serum CA125 and Bcl-2 levels and their combination in advanced epithelial ovarian cancer patients.

Methods: Healthy controls (n = 117) with no gynecologic problems and patients with ovarian carcinoma (n = 117), pathologically verified, consecutively admitted to the Istanbul University, Oncology Institute during a one-year period were investigated. Serum Bcl-2 and CA125 were determined by using enzyme linked immunosorbent assay method.

Results: The serum bcl-2 and CA125 levels were significantly higher in patients with ovarian cancer than in the control group (P < 0.001). The diagnostic sensitivity and specificity, predictive values and accuracies were calculated for each marker and their combination.

Conclusion: The best result was achieved with the combination of CA125-bcl-2. This combination fulfills the need of diagnosis of ovarian carcinoma for the best sensitivity and specificity.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / blood*
  • CA-125 Antigen / blood*
  • Case-Control Studies
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Staging
  • Neoplasms, Glandular and Epithelial / blood*
  • Neoplasms, Glandular and Epithelial / diagnosis
  • Ovarian Neoplasms / blood*
  • Ovarian Neoplasms / diagnosis
  • Prognosis
  • Proto-Oncogene Proteins c-bcl-2 / blood*
  • Sensitivity and Specificity
  • Young Adult

Substances

  • Biomarkers, Tumor
  • CA-125 Antigen
  • Proto-Oncogene Proteins c-bcl-2